SCHEMBL3022401

SCHEMBL3022401

CCc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4c(C)c(C)cc(C)c4C)CC3)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.45
MEN1 O00255 4/20 0.45
LMNA P02545 3/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
GAA P10253 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
MAPK1 P28482 1/20 0.41
THRB P10828 1/20 0.38
KDM4E B2RXH2 2/20 0.38
OGA O60502 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3651586 0.97 MEN1 (0.43) KMT2AMEN1LMNAL3MBTL1GAA
SCHEMBL3011032 0.93 KMT2A (0.46) KMT2AMEN1LMNAL3MBTL1GAA
SCHEMBL3008019 0.92 MEN1 (0.43) KMT2AMEN1LMNAL3MBTL1GAA
SCHEMBL2999817 0.91 MEN1 (0.44) KMT2AMEN1LMNAL3MBTL1GAA
SCHEMBL2998652 0.91 MEN1 (0.47) KMT2AMEN1LMNAL3MBTL1GAA
SCHEMBL3011629 0.90 NPSR1 (0.43) KMT2AMEN1LMNAGAAALDH1A1
SCHEMBL3018025 0.90 KMT2A (0.45) KMT2AMEN1LMNAL3MBTL1GAA
SCHEMBL3015027 0.89 LMNA (0.43) KMT2AMEN1LMNAL3MBTL1GAA
SCHEMBL3019426 0.89 KMT2A (0.45) KMT2AMEN1LMNAL3MBTL1GAA
SCHEMBL3009068 0.88 LMNA (0.43) KMT2AMEN1LMNAL3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KMT2A 2680/4885MEN1 454/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.